Skip Navigation
  Mission  

  Bleeding Disorders
  Diagnostic Tests  
  Message from the
  President
  Meetings  
  Membership  
  Legislative Advocacy  
  NYSDOH EMS
  Advisory
  In Case of Emergency (ICE)  
  Newsletter  
  Home Care Companies  
  Do the 5  
  John S. Wyld, Sr.
  Golf Tournament
 
  Scholarships  
  Summer Camps
  Resources  
  Donations
  Memorials  
  Special Events  
  Billboard  

 

"A cure in our time"

 
Bleeding Disorders Association of Northeastern New York, Inc.

Bleeding Disorders Association
of Northeastern New York (BDANENY), Inc.

What is Factor XI Deficiency (Hemophilia C)?

After von Willebrand disease, this is the most common bleeding disorder affecting females. The incidence of factor XI deficiency is 1 in 100,000, though it occurs more frequently among members of some ethnic groups. Its incidence is about 1 in 10,000 among Ashkenazi Jews. There are at least three different known genetic changes associated with factor XI deficiency; these vary in their effect on bleeding. Your doctor can explain exactly what type of factor XI deficiency you have and how this will affect your care and treatment.

Factor XI deficiency is usually diagnosed after injury-related bleeding, and symptoms tends to be mild. Nearly 50% of people with factor XI deficiency report no bleeding problems.

Individuals with factor XI deficiency may experience bruising, nosebleeds, or blood in their urine. Some women have prolonged bleeding after childbirth. Spontaneous bleeding is uncommon, even in people with severe factor XI deficiency. Joint bleeding is uncommon, but delayed bleeding (bleeding long after an injury has occurred) can be a problem.

Treatment Options

No commercial concentrate of factor XI is available in the United States. Accordingly, the treatment of choice for factor XI deficiency is plasma.

 

 
Valid HTML 4.01!